Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections

The Journal of Infection
Donald E LowRoomi Nusrat

Abstract

To investigate the correlation between in vitro susceptibility of isolates and clinical outcomes with telithromycin in respiratory tract infections. The activity of telithromycin was determined by in vitro susceptibility testing of key respiratory tract pathogens isolated from patients with community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute maxillary sinusitis enrolled in 14 Phase III/IV clinical trials evaluating the clinical efficacy of telithromycin. In this pooled analysis, telithromycin mode minimum inhibitory concentration (MIC) and MIC90, respectively, were: 0.016 and 0.03 mg/l against Streptococcus pneumoniae (n=626); 0.03 and 0.5 mg/l for penicillin-resistant S. pneumoniae (n=56); 0.03 and 1 mg/l for erythromycin-resistant S. pneumoniae (n=81); 2 and 4 mg/l against Haemophilus influenzae (including beta-lactamase producers; n=627); both 0.12 mg/l for Moraxella catarrhalis (n=159) and both 0.25 mg/l for Staphylococcus aureus (n=124). Telithromycin (5 or 7-10 days) resulted in overall clinical and bacteriologic success rates of 88.1% (1593/1808) and 89% (1593/1789), respectively. High levels of in vitro susceptibility to telithromycin are paralleled by high rates of clinical cure and bacteri...Continue Reading

Citations

Oct 3, 2006·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Michael BenningerDavid J Farrell
Nov 8, 2005·Journal of Clinical Microbiology·Diego FacconeAlejandra Corso
Jul 31, 2007·Future Microbiology·F BlasiV Valenti
May 4, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T M File
Nov 23, 2006·The Medical Clinics of North America·Burke A Cunha
Feb 8, 2005·The Journal of Allergy and Clinical Immunology·Thomas M File
Oct 4, 2005·Clinical Therapeutics·Megan Nguyen, Eunice P Chung
Jul 5, 2005·The American Journal of Medicine·Michael D Poole, Louis G Portugal
Dec 16, 2004·The Annals of Pharmacotherapy·Matthew ReedGregory A Hicklin
Jan 8, 2009·International Journal of Nursing Practice·Jean A GilmourHelen V Wilson
Jul 16, 2013·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Donald E StullChristoph Gerlinger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.